88 citations
,
May 2011 in “British Journal of Clinical Pharmacology” This study found that high doses of cyproterone acetate were associated with an increased risk of meningioma, especially with exposure longer than one year.
34 citations
,
November 2017 in “Gynecological Endocrinology” This report describes a case of meningioma in a transwoman treated long-term with estradiol and cyproterone acetate, suggesting possible concern over female sex steroids and meningioma risk.
5 citations
,
June 2021 in “Journal of neurology, neurosurgery and psychiatry” This study found that females exposed to high cumulative doses of cyproterone acetate had a 6–20 fold increased risk of developing meningiomas compared to those on lower doses.
59 citations
,
February 2021 in “BMJ” This study found a strong dose-related increase in the risk of intracranial meningiomas associated with high doses of cyproterone acetate, with some reduction in risk after stopping the treatment.
November 2007 in “Neuro-chirurgie/Neurochirurgie” This study reported that treatment with cyproterone acetate alone and then with incremental estrogen doses induced mild feminizing effects in late-pubertal trans-girls, with further feminization observed after adding estrogen.